Respiratory Medicine
Volume 104, Issue 5 , Pages 760-761 , May 2010

COPD patients with higher education are much less likely to adhere to prescribed daily inhaler use

Received 12 October 2009

References 

  1. VanderSchaaf K, Olson KL, Billups S, Hartsfield CL, Rice M. Self-reported inhaler use in patients with COPD. Respir Med. 2009;104(1):99–106
  2. O'Donnell DE, Lam M, Webb KA. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in COPD. Am J Respir Crit Care Med. 1999;160(2):542–549
  3. Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone–salmeterol for treatment of COPD: a randomized trial. Ann Intern Med. 2007;146(8):545–555
  4. Wedzicha JA, Calverley PM, Seemungal TA, et al. for the INSPIRE Investigators The prevention of COPD exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008;177(1):19–26
  5. Tashkin DP, Celli B, Senn S, et al. for the UPLIFT Study Investigators A 4-year trial of tiotropium in COPD. N Engl J Med. 2008;359(15):1543–1554
  6. Calverley PM, Anderson JA, Celli B, et al. for the TORCH investigators Salmeterol and fluticasone propionate and survival in COPD. N Engl J Med. 2007;356(8):775–789
  7. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe COPD: the ISOLDE trial. BMJ. 2000;320(7245):1297–1303
  8. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA. 1994;272(19):1497–1505
  9. Kainu A, Lindqvist A, Sarna S, Lundbäck B, Sovijärvi A. FEV1 response to bronchodilation in an adult urban population. Chest. 2008;134(2):387–393
  10. Jakeways N, McKeever T, Lewis SA, Weiss ST, Britton J. Relationship between FEV1 reduction and respiratory symptoms in the general population. Eur Respir J. 2003;21(4):658–663
  11. Niewoehner DE, Lokhnygina Y, Rice K, et al. Risk indexes for exacerbations and hospitalizations due to COPD. Chest. 2007;131(1):20–28
  12. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with COPD: a systematic review and meta-analysis. JAMA. 2008;300(12):1439–1450
  13. Lee TA, Pickard AS, Au DH, Bartle B, Weiss KB. Risk for death associated with medications for recently diagnosed COPD. Ann Intern Med. 2008;149(6):380–390
  14. Crim C, Calverley PM, Anderson JA, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J. 2009;34(3):641–647
  15. Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in COPD: a meta-analysis. Arch Intern Med. 2009;169(3):219–229
  16. Travers J, Marsh S, Caldwell B, et al. External validity of randomized controlled trials in COPD. Respir Med. 2007;101(6):1313–1320
  17. Suissa S, Ernst P, Vandemheen KL, Aaron SD. Methodological issues in therapeutic trials of COPD. Eur Respir J. 2008;31(5):927–933

PII: S0954-6111(10)00051-X

doi: 10.1016/j.rmed.2009.10.031

Respiratory Medicine
Volume 104, Issue 5 , Pages 760-761 , May 2010

Article Tools